Biotech Archives - Page 18 of 733

1 minute read

Autolus Therapeutics Presents Additional Data Analysis Of Pivotal Phase 2 Felix Study Of obe-cel For Adult r/r B-all In An Oral Presentation At ASCO

May 31, 8:11 AM

The majority of patients that responded to obe-cel showed durable responses with the potential for a long-term plateau of survival outcomes40% patients are in ongoing remission without subsequent stem cell transplant

AUTL

1 minute read

Pfizer’s LORBRENA CROWN Study Shows Majority Of Patients With ALK-Positive Advanced Lung Cancer Living Beyond 5-Years Without Disease Progression

By Benzinga Newsdesk

May 31, 8:04 AM

An unprecedented 60% of patients remain alive without disease progression after five yearsUpdated results show continued 81% reduction in risk of progression or death and 94% reduction in progression of brain metastases

PFE

2 minute read

Novo Integrated Sciences Shares Surge 70% After Company Secures $78M Funding From HSBC For Acquisition Of Ophir Collection

By Benzinga Neuro

May 30, 11:17 PM

Novo Integrated Sciences surged 70.29% in after-hours trading to $0.77 following HSBC's confirmation of a $78 million Standby Letter of Credit.

NVOS

1 minute read

Oncocyte VitaGraft Kidney Study Results Published In The New England Journal Of Medicine

By Benzinga Newsdesk

May 30, 4:50 PM

Late-breaking presentation of data at American Transplant Congress on Monday, June 3Data show potential to monitor for therapeutic efficacy and recurrencePotential repeat testing opportunities with claims

OCX

1 minute read

Oncternal Completes Enrollment And Dosing Initiated For 5th Dose Cohort Of Phase 1/2 Study Of ONCT-534 For The Treatment Of R/R Metastatic Castration-Resistant Prostate Cancer

By Benzinga Newsdesk

May 30, 4:45 PM

Oncternal Therapeutics, Inc. (NASDAQ:ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that enrollment has been completed and dosing initiated for

ONCT

1 minute read

NextCure To Present Phase 1b Data On NC410 And Pembrolizumab Combination at ASCO 2024 June 1, 2024

By Benzinga Newsdesk

May 30, 4:43 PM

Of the evaluable ICI-naïve MSS/MSI-L CRC patients without liver metastasis, there were 2 confirmed ongoing PRs and a disease control rate of 51% Of the 7 evaluable ovarian cancer patients, there were 3 PRs and a

NXTC

1 minute read

Ultragenyx Announces Top-Line Results From Phase 3 Study of DTX401 Gene Therapy For Glycogen Storage Disease Type Ia

By Benzinga Newsdesk

May 30, 4:00 PM

Treatment with DTX401 resulted in a statistically significant reduction in daily cornstarch intake at Week 48 (p<0.0001) with maintenance of glucose control Company will host investor call today at 5:00 p.m.

RARE

2 minute read

New Weight Loss ETF Is Essentially A Play On Eli Lilly, Novo Nordisk

By Surbhi Jain

May 30, 3:36 PM

New OZEM ETF offers investors exposure to weight-loss sector through top pharmaceutical companies Eli Lilly and Novo Nordisk, with potential for high growth but also risks.

LLY

1 minute read

INmune Bio To Join Russell 3000 Index, Effective At The Open Of Us Equity Markets On Monday, July 1

By Benzinga Newsdesk

May 30, 8:18 AM

INmune Bio Inc. (NASDAQ:INMB) (the "Company"), a clinical-stage inflammation and immunology company, is set to join the broad-market Russell 3000® Index at the conclusion of the 2024 Russell US Indexes

INMB

1 minute read

4D Molecular Therapeutics To Present Interim Data From Aerosolized 4D-710 Phase 1/2 AEROW Clinical Trial For Cystic Fibrosis At 47 European Cystic Fibrosis Conference

By Benzinga Newsdesk

May 30, 8:07 AM

Interim clinical data will be presented by Jennifer L. Taylor-Cousar, M.D., Principal Investigator of the AEROW clinical trial at the 47th European Cystic Fibrosis Conference on Thursday, June 6, 2024 at 5:00 p.m.

FDMT